Werewolf Therapeutics (HOWL) Net Margin (2022 - 2026)

Werewolf Therapeutics (HOWL) has reported Net Margin for 4 consecutive years, with 33.14% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Margin changed N/A year-over-year to 33.14% in Q2 2026; TTM through Jun 2026 was 161.14%, a 48867886.0% increase from a year earlier, with the FY2024 full-year figure at 3767.21%, down 358556.0% from the prior year.
• Net Margin was 33.14% for Q2 2026 at Werewolf Therapeutics, up from 135373.33% in the prior quarter.
• Over five years, Net Margin peaked at 33.14% in Q2 2026 and troughed at 135373.33% in Q4 2024.
• A 4-year average of 12829.66% and a median of 243.64% in 2023 frame the typical range for Net Margin.
• Across the five-year window, Net Margin surged 28906 bps in 2023 and tumbled 13457407 bps in 2024, its largest moves.
• Over 4 years, Net Margin stood at 163.81% in 2022, then sank by 388 bps to 799.27% in 2023, then tumbled by 16837 bps to 135373.33% in 2024, then soared by 100 bps to 33.14% in 2026.
• The last three Net Margin figures came in at 33.14% (Q2 2026), 135373.33% (Q4 2024), and 1601.84% (Q2 2024), per Business Quant data.